Novartis Ag (NVS) Short-Term Debt issuances (2009 - 2026)

Novartis Ag has disclosed Short-Term Debt issuances across 18 years of filings, most recently posting $208.0 million for Q2 2026.

• In Q2 2026, Short-Term Debt issuances fell 75.53% year-over-year to $208.0 million; the TTM figure through Jun 2026 stood at $1.8 billion (down 24.75% YoY), while the FY2025 annual figure was $5.0 million, down 99.48% from the prior year.
• Short-Term Debt issuances came in at $208.0 million for Q2 2026 at Novartis Ag, down from $747.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $1.8 billion in Q4 2024 to a low of -$1.2 billion in Q4 2022.
• Average Short-Term Debt issuances over 5 years is $376.7 million, with a median of $562.5 million recorded in 2024.
• Year-over-year, Short-Term Debt issuances slumped 148.0% in 2023 and soared 180.25% in 2024.
• Over 5 years, Short-Term Debt issuances stood at -$1.2 billion in 2022, then surged by 156.35% to $674.0 million in 2023, then surged by 165.43% to $1.8 billion in 2024, then decreased by 21.41% to $1.4 billion in 2025, then slumped by 85.21% to $208.0 million in 2026.
• Per Business Quant data, the three most recent Short-Term Debt issuances figures were $208.0 million in Q2 2026, $747.0 million in Q1 2026, and $1.4 billion in Q4 2025.